Skip to main content

Table 2 Multivariable analysis concerning overall and event-free survival

From: Lysyl oxidase expression is associated with inferior outcome and Extramedullary disease of acute myeloid leukemia

Factor Overall Survival Event-free Survival
HR
[95% CI]
p-value HR
[95% CI]
p-value
Low Risk Karyotype 0.486
[0.287–0.825]
0.007 0.553
[0.374–0.818]
0.003
High Risk Karyotype 1.858
[1.404–2.459]
< 0.001 1.407
[1.088–1.818]
0.009
Higher Agea 1.034
[1.021–1.047]
< 0.001 1.021
[1.011–1.032]
< 0.001
FLT3-ITD positivity 1.834
[1.376–2.445]
< 0.001 1.430
[1.109–1.843]
0.006
NPM1 mutation 0.527
[0.385–0.723]
< 0.001 0.530
[0.408–0.689]
< 0.001
Logarithmic (to base 10) WBC 1.191
[0.962–1.474]
0.109 1.030
[0.857–1.237]
0.754
Bone Marrow Blast Count at Day 15 after Induction Chemotherapyb 1.010
[1.005–1.014]
< 0.001 1.028
[1.023–1.033]
< 0.001
Extramedullary Disease 1.203
[0.698–2.076]
0.506 0.888
[0.535–1.476]
0.648
high LOX Expression 0.956
[0.711–1.285]
0.766 1.034
[0.804–1.329]
0.795
Interaction of Extramedullary Disease and high LOX Expression 2.246
[1.106–4.559]
0.025 2.478
[1.264–4.857]
0.008
  1. Table 2 Results of multivariate testing for overall survival and event-free survival including HR, 95% CI and p-values
  2. Abbreviations: HR hazard ratio, 95% CIs 95% confidence interval
  3. aage as a continuous variable in years
  4. bbone marrow blast count as a continuous variable in percent